Diabetic Retinopathy Market Report

Diabetic Retinopathy Market Analysis Report By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), And Segment Forecasts, 2018 - 2025

  • Published Date: Feb, 2018
  • Base Year for Estimate: 2016
  • Report ID: 978-1-68038-466-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2015
  • Number of Pages: 81

Industry Insights 

The global diabetic retinopathy market size was valued at USD 5.81 billion in 2016 and is anticipated to grow at a CAGR of 6.3% over the forecast period. Diabetic retinopathy is considered as a serious sight threatening complication that results due to long term diabetes. It is a disorder, causing progressive damage to the retina and affecting the retinal circulatory system. The treatment line selection for diabetic retinopathy depends on the extremity of the condition and may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy.

Increasing prevalence of diabetes along with growing incidence of blindness due to diabetes is anticipated to propel the market growth over the forecast period. According to the estimates of the WHO, the number of people with diabetes has increased from 108 million adults in 1980 to around 422 million adults in 2014. In addition, the global prevalence of diabetes has also doubled, at nearly 8.5% in the adult population in 2014, as compared to 4.7% in 1980.

Global diabetic retinopathy market

About 78.0% cases of diabetic retinopathy were reported in 2013, as per the statistics given by the Department of Assistive and Rehabilitative Services (DARS), Texas that could eventually lead to loss of vision. As per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the leading causes of blindness in UK in 2017.

It was estimated, that within 20 years of diagnosis, most people with Type 1 diabetes and a majority of people with Type 2 diabetes, suffered from retinopathy to some extent. As per estimates of the screening conducted by the All India Ophthalmological Society in 2014, the prevalence of diabetic retinopathy in the data set they collected was around 21.7%.

Moreover, the rising global geriatric population is expected to heighten the susceptibility towards chronic disorders such as cardiovascular disorders, diabetes, and sleep disorders. The development of proliferative diabetic retinopathy is multi-fold in patients aged above 65 years with a history of diabetes.

According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S., aged 65 years and over were projected to increase from around 46 million in 2016 to over 98 million by 2060. In addition, the population aged over 65 years was expected to grow from around 15% of the total population to around 24%. 

Increasing disposable income and the fear of losing vision have increased the spending by patients to avail necessary treatment. Availability of advanced technology and minimal pain inducing laser procedure with quick recovery is expected to promote patients’ willingness to adopt surgical treatments.

Type Insights

On the basis of type, the segments are non-proliferative and proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy (NPDR) dominated the overall market in 2016 owing to presence of large number of patients within the bracket of less than 10 years of diabetic history. Non-proliferative diabetic retinopathy, also called background retinopathy, is the most common diabetic eye condition and is also the leading cause of adult blindness.

Non-proliferative retinopathy typically changes from mild to moderate and then leads to severe conditions. Increased prevalence of diabetes, and non-compliant retinal screening in diabetic patients are anticipated to boost the growth of non-proliferative diabetic retinopathy market. Further, the use of drugs is increasing to cure moderate proliferation with no additional complication has contributed to revenue generation.

Proliferative diabetic retinopathy is the most advanced stage of this condition, in which fragile blood vessels leak blood into the eye resulting in blurred vision. Diabetic retinopathy can be diagnosed through comprehensive eye exams such as visual acuity test, dilated eye exam, and tonometry. Proliferative retinopathy is generally treated by laser surgery, which helps in shrinking the fragile blood vessels. Proliferative DR is anticipated to grow with the highest CAGR over the forecast period. This growth is seen due to rising target population, and geriatric population reaching the proliferative stage of retinopathy.

Management Insights

On the basis of management, the market is segmented into four categories namely-anti-VEGF treatment, laser surgery, intraocular steroid injection, and vitrectomy. Anti-VEGF segment dominated the market in 2016 owing to high applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment, better treatment and faster recovery. The major anti-VEGF agents currently used include Eylea, Avastin, Lucentis, and Macugen.  The increasing usage of Lucentis due to favourable outcomes further propels the growth of the segment worldwide.

Global diabetic retinopathy market

Laser photocoagulation is a highly effective treatment for diabetic retinopathy patients, therefore, this segment is expected to be the fastest growing by 2025.  Laser surgery can be done by two methods namely, scatter photocoagulation and focal laser surgery. Scatter photocoagulation is prominently used to manage proliferative DR, whereas focal is used for photographic examination prior to the surgery to identify the leakage areas around the macula.

The anticipated rise in the number of proliferative diabetic retinopathy cases during the forecast period is expected to boost the market share of the segment. Technological advancement and availability of upgraded products and equipment are further expected to boost the segmental growth.

Regional Insights 

North America region accounted for the largest share owing to the supportive reimbursement policies, and increasing prevalence of diabetes. High market penetration of Avastin, Eylea and Lucentis which are anti-VEGF drugs, is one of the major factors contributing to the large regional share. Moreover, the market is driven by the presence of high healthcare expenditure, rising patient awareness levels, and sophisticated healthcare infrastructure.

Europe commanded the second largest share in the diabetic retinopathy market in 2016. The expanding healthcare infrastructure along with favorable reimbursement framework in the developed European countries is expected to propel market growth during the forecast period. In addition, presence of high unmet medical needs in the emerging Eastern European markets coupled with rapidly improving healthcare infrastructure in the region is expected to fuel growth.

The emerging nations such as Japan and China in Asia Pacific are anticipated to witness lucrative growth during the forecast period owing to rising disposable income, increasing geriatric population, expanding research funding for diabetes, innovation in diagnostics, and large target patient pool.

China’s market is expected to witness rapid growth over the forecast period. Japan is the largest market in the Asia Pacific region mainly on account of the presence of high healthcare expenditure and rising disposable income. Moreover, growing usage of Lucentis is expected to drive market growth in this region.

Diabetic Retinopathy Market Share Insights

The global market is consolidated in nature and is highly competitive due to the presence of large number of players. The major players are Novartis AG, Bayer Healthcare, Regeneron Pharmaceuticals Inc., ThromboGenics, Actavis Plc, Sirnaomics, Genentech, Alimera Sciences, Glycadia Pharmaceuticals, Ampio Pharmaceuticals, Kowa Group, and BCN Peptides.

Companies are adopting strategic initiatives such as acquisitions, mergers, geographical expansion and product development in order to advance their businesses and increase their outreach in the market. For instance, ThromboGenics initiated a partnership with Novartis (Alcon) to assist in the marketing and commercialization of JETREA outside the U.S.

Similarly, Alimera initiated sale of ILUVIEN in Germany and the UK, thereby entering the European market. This initiative was aimed at entering new markets and increasing revenues.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2015

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, & MEA

Country scope

U.S., Canada, UK, Germany, France, Japan, China, Brazil, and South Africa

Report coverage

Revenue, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analysts working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the global diabetic retinopathy market report on the basis of type, management, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Proliferative diabetic retinopathy

    • Non-proliferative diabetic retinopathy

  • Management Outlook (Revenue, USD Million, 2014 - 2025)

    • Anti-VEGF

    • Intraocular steroid injection

    • Laser surgery

    • Vitrectomy

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East and Africa (MEA)

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
Compass Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified